|
23
|
| 62 |
VEGFA
|
|
increases_activity of
|
KDR
|
in endothelial cells (BTO:0001176)
|
| 13109 |
VEGFA
|
|
increases_phosphorylation of
|
KDR
|
in endothelial cells (BTO:0001176)
|
|
16966330
|
Amyotrophic lateral sclerosis
|
|
30
|
| 73 |
VEGFA
|
|
increases_activity of
|
CDC42
|
in endothelial cells (BTO:0001176)
|
|
14724572
|
Amyotrophic lateral sclerosis
|
|
102
|
| 348 |
VEGFA-mut
|
|
decreases_expression of
|
VEGFA
|
|
| 349 |
VEGFA-mut
|
|
decreases_quantity of
|
VEGFA
|
|
|
12847526
|
Amyotrophic lateral sclerosis
|
|
104
|
| 357 |
VEGFA
|
|
decreases_activity of
|
motor neuron degeneration
|
|
|
12847526
|
Amyotrophic lateral sclerosis
|
|
105
|
| 371 |
VEGFA-mut
|
|
decreases_quantity of
|
VEGFA
|
in neural tissue
|
| 373 |
VEGFA-mut
|
|
decreases_quantity of
|
VEGFA
|
in cultured fibroblasts
|
|
11381259
|
Amyotrophic lateral sclerosis
|
|
134
|
| 485 |
sciatic nerve
|
|
affects transport of
|
VEGFA
|
|
|
15568021
|
Amyotrophic lateral sclerosis
|
|
135
|
| 488 |
VEGFA
|
|
increases_activity of
|
neuromuscular junction
|
|
| 489 |
VEGFA
|
|
decreases_activity of
|
Amyotrophic lateral sclerosis
|
|
|
15568021
|
Amyotrophic lateral sclerosis
|
|
201
|
| 797 |
TNFRSF1A
|
|
affects_expression of
|
VEGFA
|
|
|
18413601
|
Amyotrophic lateral sclerosis
|
|
202
|
| 803 |
VEGFA
|
|
decreases_activity of
|
neuron death
|
|
|
18413601
|
Amyotrophic lateral sclerosis
|
|
203
|
| 806 |
TNF
|
|
increases_expression of
|
VEGFA
|
|
|
18413601
|
Amyotrophic lateral sclerosis
|
|
237
|
| 982 |
VEGFA
|
|
increases_activity of
|
angiogenesis
|
|
|
9618543
|
Amyotrophic lateral sclerosis
|
|
239
|
| 987 |
VEGFA
|
|
increases_expression of
|
FLT1
|
|
|
9618543
|
Amyotrophic lateral sclerosis
|
|
249
|
| 1027 |
electroconvulsive seizure
|
|
increases_expression of
|
VEGFA
|
|
| 1028 |
Fluoxetine
|
|
increases_expression of
|
VEGFA
|
|
| 1029 |
Desipramine
|
|
increases_expression of
|
VEGFA
|
|
|
17360578
|
Amyotrophic lateral sclerosis
|
|
264
|
| 1087 |
VEGFA
|
|
decreases_activity of
|
behavioral despair
|
|
|
17360578
|
Amyotrophic lateral sclerosis
|
|
272
|
| 1110 |
VEGFA
|
|
decreases_activity of
|
synaptic transmission
|
|
|
16192378
|
Amyotrophic lateral sclerosis
Epilepsy
|
|
285
|
| 1145 |
seizures
|
|
increases_quantity of
|
VEGFA
|
|
|
18065154
|
Amyotrophic lateral sclerosis
Status epilepticus
|
|
287
|
| 1148 |
VEGFA
|
|
decreases_activity of
|
neurodegeneration
|
|
|
18065154
|
Amyotrophic lateral sclerosis
|
|
289
|
| 1155 |
response to hypoxia
|
|
increases_expression of
|
VEGFA
|
exposed to atmospheric hypoxia of 10, 3 and 1% O(2) for 24 h
|
|
19444281
|
Amyotrophic lateral sclerosis
|
|
293
|
| 1175 |
SOD1-p.G93A
|
|
decreases_expression of
|
VEGFA
|
|
|
19444281
|
Amyotrophic lateral sclerosis
|
|
303
|
| 1210 |
learning
|
|
increases_expression of
|
VEGFA
|
|
| 1211 |
enriched environment
|
|
increases_expression of
|
VEGFA
|
|
|
15258583
|
Amyotrophic lateral sclerosis
|
|
304
|
| 1212 |
VEGFA
|
|
increases_phosphorylation of
|
KDR
|
|
| 1214 |
VEGFA
|
|
increases_activity of
|
learning or memory
|
|
|
15258583
|
Amyotrophic lateral sclerosis
|
|
312
|
| 1234 |
VEGFA
|
|
increases_activity of
|
angiogenesis
|
|
| 1237 |
VEGFA
|
|
increases_activity of
|
neurogenesis
|
|
|
15258583
|
Amyotrophic lateral sclerosis
|
|
320
|
| 1386 |
glioma cell line
|
|
increases_expression of
|
VEGFA
|
|
| 1387 |
IL1B
|
|
increases_expression of
|
VEGFA
|
|
| 1388 |
MAPK14
|
|
increases_expression of
|
VEGFA
|
|
| 1389 |
MAPK8
|
|
increases_expression of
|
VEGFA
|
|
|
16964394
|
Amyotrophic lateral sclerosis
|
|
379
|
| 1562 |
Lipophilic metal chelator DP-460
|
|
increases_expression of
|
VEGFA
|
in SOD1(G93A) transgenic mice
|
|
17630988
|
Amyotrophic lateral sclerosis
|
|
618
|
| 3277 |
VEGFA
|
|
increases_activity of
|
receptor internalization
|
|
|
12649282
|
Amyotrophic lateral sclerosis
|
|
622
|
| 3286 |
VEGFA
|
|
decreases_activity of
|
neuron apoptotic process
|
in spinal cord; in serum-deprived cultures
|
| 3290 |
VEGFA
|
|
decreases_activity of
|
motor neuron degeneration
|
in spinal cord cultures; in serum-deprived cultures
|
| 3293 |
VEGFA
|
|
increases_activity of
|
AKT1
|
in spinal cord; in serum-deprived cultures
|
| 3300 |
VEGFA
|
|
increases_phosphorylation of
|
AKT1
|
in spinal cord; in serum-deprived cultures
|
| 3306 |
VEGFA
|
|
decreases_activity of
|
p38 MAPK
|
in spinal cord; in serum-deprived cultures
|
| 3308 |
VEGFA
|
|
decreases_phosphorylation of
|
p38 MAPK
|
in spinal cord; in serum-deprived cultures
|
| 3312 |
VEGFA
|
|
affects_activity of
|
phosphatidylinositol 3-kinase signaling
|
in spinal cord; in serum-deprived cultures
|
| 3315 |
VEGFA
|
|
increases_quantity of
|
BCL2
|
in spinal cord; in serum-deprived cultures
|
|
19041930
|
Amyotrophic lateral sclerosis
|
|
627
|
| 3324 |
VEGFA
|
|
increases_activity of
|
decreased susceptibility to neuronal excitotoxicity
|
in spinal cord motoneurons; exposed to THA (a glutamate transporter inhibitor) to induce chronic glutamate neurotoxicity
|
| 3325 |
VEGFA
|
|
decreases_activity of
|
motor neuron degeneration
|
in spinal cord motoneurons; exposed to THA (a glutamate transporter inhibitor) to induce chronic glutamate neurotoxicity
|
| 3326 |
VEGFA
|
|
increases_activity of
|
MAPK3
|
in spinal cord motoneurons
|
| 3327 |
VEGFA
|
|
increases_phosphorylation of
|
MAPK3
|
in spinal cord motoneurons
|
| 3328 |
VEGFA
|
|
increases_activity of
|
MAPK1
|
in spinal cord motoneurons
|
| 3329 |
VEGFA
|
|
increases_phosphorylation of
|
MAPK1
|
in spinal cord motoneurons
|
| 3330 |
VEGFA
|
|
increases_activity of
|
AKT1
|
in spinal cord motoneurons
|
| 3331 |
VEGFA
|
|
increases_phosphorylation of
|
AKT1
|
in spinal cord motoneurons
|
| 3332 |
VEGFA
|
|
increases_activity of
|
phosphatidylinositol 3-kinase signaling
|
in spinal cord motoneurons
|
| 3333 |
VEGFA
|
|
increases_activity of
|
MAPK cascade
|
in spinal cord motoneurons
|
| 3334 |
VEGFA
|
|
increases_quantity of
|
BCL2
|
in spinal cord motoneurons; exposed to THA (a glutamate transporter inhibitor) to induce chronic glutamate neurotoxicity
|
| 3335 |
VEGFA
|
|
increases_quantity of
|
BIRC5
|
in spinal cord neurons; exposed to THA (a glutamate transporter inhibitor) to induce chronic glutamate neurotoxicity
|
|
18182045
|
Amyotrophic lateral sclerosis
|
|
655
|
| 3493 |
(5-[N-methyl-N-propargylaminomethyl]-8-hydroxyquinoline)
|
|
increases_expression of
|
VEGFA
|
|
| 3495 |
(5-[4-propargylpiperazin-1-ylmethyl]-8-hydroxyquinoline)
|
|
increases_expression of
|
VEGFA
|
|
|
19638399
|
Amyotrophic lateral sclerosis
|
|
834
|
| 4941 |
XBP1
|
NOT |
affects_expression of
|
VEGFA
|
|
|
19805353
|
Neurological
Amyotrophic lateral sclerosis
|
|
835
|
| 4942 |
ERN1
|
|
affects_quantity of
|
VEGFA
|
|
|
19805353
|
Neurological
Amyotrophic lateral sclerosis
|
CIDeRplus